분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-05-29 16:23:49 , Hit : 1656
 Pfizer Abandons AstraZeneca Takeover Bid



May 26, 2014  Agence France-Presse | IndustryWeek

.


What is in this article?:

Pfizer Abandons AstraZeneca Takeover Bid
'Culture of Innovation'



U.S. drugmaker Pfizer abandons its controversial bid to acquire British rival AstraZeneca after its final $117 billion offer was rejected last week.
..




(Photo by Christopher Furlong/Getty Images)




Advertisement


<script language="JavaScript" type="text/javascript"> document.write('<a href="http://adclick.g.doubleclick.net/aclk?sa=L&ai=B1_jFs9-GU-7AENCp9gX59oLQD7uByYQFAAAAEAEgm9CUHjgAWPPG35ujAWCbg-mEnCmyARR3d3cuaW5kdXN0cnl3ZWVrLmNvbboBCWdmcF9pbWFnZcgBCdoBU2h0dHA6Ly93d3cuaW5kdXN0cnl3ZWVrLmNvbS9nbG9iYWwtZWNvbm9teS9wZml6ZXItYWJhbmRvbnMtYXN0cmF6ZW5lY2EtdGFrZW92ZXItYmlkmAKQvwXAAgLgAgDqAhwvMzgzNC9pdy5ob21lL2dsb2JhbF9lY29ub215-AKB0h6QA-wJmAPgA6gDAeAEAaAGFg&num=0&sig=AOD64_0DT7-PAk8sJxBsgVxuQh42zfNimQ&client=ca-pub-0098407289527799&adurl=http://clk.atdmt.com/SLC/go/473454965/direct/01/" target="_blank"><img src="http://view.atdmt.com/SLC/view/473454965/direct/01/1150253062"/></a>'); </script> <noscript> <a href="http://adclick.g.doubleclick.net/aclk?sa=L&ai=B1_jFs9-GU-7AENCp9gX59oLQD7uByYQFAAAAEAEgm9CUHjgAWPPG35ujAWCbg-mEnCmyARR3d3cuaW5kdXN0cnl3ZWVrLmNvbboBCWdmcF9pbWFnZcgBCdoBU2h0dHA6Ly93d3cuaW5kdXN0cnl3ZWVrLmNvbS9nbG9iYWwtZWNvbm9teS9wZml6ZXItYWJhbmRvbnMtYXN0cmF6ZW5lY2EtdGFrZW92ZXItYmlkmAKQvwXAAgLgAgDqAhwvMzgzNC9pdy5ob21lL2dsb2JhbF9lY29ub215-AKB0h6QA-wJmAPgA6gDAeAEAaAGFg&num=0&sig=AOD64_0DT7-PAk8sJxBsgVxuQh42zfNimQ&client=ca-pub-0098407289527799&adurl=http://clk.atdmt.com/SLC/go/473454965/direct/01/" target="_blank"><img border="0" src="http://view.atdmt.com/SLC/view/473454965/direct/01/"></a> </noscript>  
.


NEW YORK – U.S. drugmaker Pfizer (IW 500/22) said on Monday it had abandoned its controversial bid to acquire British rival AstraZeneca (IW 1000/57) after its final $117 billion offer was rejected last week.

The announcement was the latest twist to a long-running saga that drew widespread attention over fears that British jobs and research capability would be lost and accusations that the tie-up was a cynical ploy by Pfizer to pay less tax.

Pfizer's takeover would have been the biggest deal of its kind in the pharmaceutical industry.

"Following the AstraZeneca board's rejection of the proposal, Pfizer announces that it does not intend to make an offer for AstraZeneca," the New York-based company said in a statement.

Pfizer had said that the combined company would deliver an expanded product pipeline, deep potential cost cuts and significant tax savings.

"We continue to believe that our final proposal was compelling and represented full value for AstraZeneca based on the information that was available to us," said Ian Read, chairman and CEO of Pfizer. "As we said from the start, the pursuit of this transaction was a potential enhancement to our existing strategy. We will continue our focus on the execution of our plans, bringing forth new treatments to meet patients' needs and remaining responsible stewards of our shareholders' capital."

Pfizer's proposal also included a controversial plan to re-domicile the combined company in Britain for tax purposes, in a move that would help it avoid paying billions of dollars in tax to the U.S. government.

AstraZeneca chairman Leif Johansson had attacked the U.S. pharmaceutical giant's pursuit of the firm, decrying it as "fundamentally driven by the corporate financial benefits to its shareholders of cost savings and tax minimisation."

'Culture of Innovation'



Responding to Pfizer's withdrawal on Monday, Johansson said AstraZeneca "would continue building on the momentum we have already demonstrated as an independent company."

"We have attractive growth prospects and a rapidly progressing pipeline," Johansson said. "AstraZeneca has a culture of innovation, with science at the heart of everything we do."

AstraZeneca chief executive Pascal Soriot had resisted the Pfizer overtures, bullishly advising shareholders that the company's revenues would almost double to $45 billion by 2023.

But analysts have expressed skepticism that Soriot's forecasts will prove accurate, speculating that AstraZeneca's sales by 2023 would remain in the range of $28 billion to $31 billion.

Pfizer's play for AstraZeneca comes as global pharmaceutical giants maneuver to cope with lost revenues from public-sector cutbacks in health care and patent expirations.

But Pfizer's withdrawal does not necessarily signal the end of the company's pursuit of AstraZeneca, although under British law the U.S. company must now wait six months before tabling another offer.

It could also make a higher bid in three months if AstraZeneca's board agrees to a fresh round of takeover talks.

Monday's developments did not immediately impact the U.S. and London stock markets, which were closed due to holidays. Pfizer's share price had slipped by 0.6% in Friday's trade to $29.49.

Copyright Agence France-Presse, 2014








927   바이러스를 저지시키는 방법  이성욱 2014/08/15 1651
926   금발은 어떻게 생겨날까? - DNA 글자 하나가 머리칼의 색깔을 바꾼다.  이성욱 2014/06/05 1652
925   뇌종양이 남성에서 더 흔한 이유?  이성욱 2014/08/06 1655
924   DNA가 비슷한 배우자를 선택하는 경향  이성욱 2014/05/23 1656
  Pfizer Abandons AstraZeneca Takeover Bid  이성욱 2014/05/29 1656
922   STAP 논문, 결국 62일 만에...  이성욱 2014/04/02 1660
921   유전자요법을 이용한 신경근육접합부 결함 치료  이성욱 2014/09/24 1665
920   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1665
919   US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments  이성욱 2015/01/08 1665
918   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1667
917   존재하지 않았던 STAP 줄기세포  이성욱 2014/06/05 1668
916   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1668
915   텔로머레이즈 기반 유전자 요법으로 심장마비 치료  이성욱 2014/12/24 1669
914   야심찬 브레인 프로젝트  이성욱 2014/06/11 1681
913   박테리아와 바이러스에 존재하는 나노 바이오모터(biomotor)  이성욱 2014/07/18 1682
912   치료가 어려운 C형 간염에 대한 새로운 경구 병용 요법  이성욱 2014/08/01 1682
911   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1687
910   Merck hepatitis C drugs work in HIV co-infected patients -study  이성욱 2014/03/08 1688
909   Targeting DNA  이성욱 2012/06/07 1698
908   전령 RNA에서의 슈도유리딜화  이성욱 2014/09/19 1698

[이전 10개] [1]..[11][12][13][14][15][16][17] 18 [19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN